Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $55.00 at Robert W. Baird

Mirum Pharmaceuticals (NASDAQ:MIRM) had its target price boosted by Robert W. Baird from $50.00 to $55.00 in a research note issued to investors on Thursday morning,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

Several other brokerages have also issued reports on MIRM. Citigroup increased their price target on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. HC Wainwright reissued a “buy” rating and issued a $66.00 price target on shares of Mirum Pharmaceuticals in a research report on Wednesday, November 13th. Ten equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $57.60.

Mirum Pharmaceuticals Price Performance

Shares of NASDAQ MIRM opened at $46.97 on Thursday. Mirum Pharmaceuticals has a 1 year low of $23.14 and a 1 year high of $54.23. The stock has a market capitalization of $2.25 billion, a P/E ratio of -23.25 and a beta of 0.96. The company’s 50-day moving average is $46.84 and its 200 day moving average is $43.35. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its earnings results on Wednesday, February 26th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.22). The firm had revenue of $99.41 million for the quarter, compared to analysts’ expectations of $96.64 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. On average, sell-side analysts expect that Mirum Pharmaceuticals will post -1.43 earnings per share for the current year.

Insider Buying and Selling at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 750 shares of the company’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $42.82, for a total transaction of $32,115.00. Following the transaction, the senior vice president now owns 2,926 shares in the company, valued at approximately $125,291.32. This represents a 20.40 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Peter Radovich sold 1,998 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total transaction of $85,554.36. Following the completion of the sale, the chief operating officer now owns 27,015 shares of the company’s stock, valued at $1,156,782.30. This represents a 6.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 40,915 shares of company stock worth $1,897,920. Insiders own 22.87% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MIRM. Jones Financial Companies Lllp raised its stake in Mirum Pharmaceuticals by 100.0% during the 4th quarter. Jones Financial Companies Lllp now owns 714 shares of the company’s stock valued at $30,000 after buying an additional 357 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Mirum Pharmaceuticals in the fourth quarter worth $35,000. GF Fund Management CO. LTD. purchased a new stake in Mirum Pharmaceuticals during the fourth quarter valued at $42,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Mirum Pharmaceuticals by 22.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock valued at $67,000 after acquiring an additional 318 shares during the period. Finally, R Squared Ltd purchased a new position in Mirum Pharmaceuticals in the fourth quarter worth about $69,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.